Gelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel Technology
19. Dezember 2024 08:30 ET
|
Gelteq Limited
NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a global biotechnology company that specializes in the formulation, development, and...
Gelteq Receives FDA Approval of its Suitability Petition for New Animal Drug
17. Dezember 2024 08:30 ET
|
Gelteq Limited
NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and biotechnology company focused on developing and commercializing white label...
Gelteq to Participate in the Benchmark Company 13th Annual Discovery Investor Conference
09. Dezember 2024 08:30 ET
|
Gelteq Limited
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company that is focused on developing and commercializing white...
Gelteq Announces Largest U.S. Customer Increases Initial Order by 50% to Meet Growing Market Demand
02. Dezember 2024 08:30 ET
|
Gelteq Limited
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company that is focused on developing and commercializing white...
Gelteq Announces 400,000 Units Enter into Production in November 2024
26. November 2024 08:30 ET
|
Gelteq Limited
NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company focused on developing and commercializing white label...
Gelteq Expands Operations in United States with Appointment of Adam Bendell as President of U.S. Operations to Scale Domestic Business
12. November 2024 09:00 ET
|
Gelteq Limited
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company that is focused on developing and commercializing white...
Gelteq Limited Closes US$5.2 Million Initial Public Offering
30. Oktober 2024 10:00 ET
|
Gelteq Limited
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a global biotechnology company that specializes in the formulation, development, and manufacturing of...
Gelteq Limited Prices US$5.2 Million Initial Public Offering
28. Oktober 2024 21:50 ET
|
Geltec Limited
NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a global biotechnology company that specializes in the formulation, development, and manufacturing of...
Gelteq Strengthens Partnership with Monash Innovation Labs
06. August 2024 09:00 ET
|
Gelteq Pty Ltd
MELBOURNE, Australia, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a global biotechnology company that specializes in the formulation, development, and manufacturing...
Gelteq Granted First U.S. Patent for Gel-based Blood Glucose Testing Product and Methodology
13. September 2021 11:00 ET
|
Gelteq Pty Ltd
MELBOURNE, Australia, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Gelteq Pty Ltd, a global leader in ingestible gel technology for healthcare, nutrition and sports, has been granted a U.S. patent (No....